Clinical stage IA (limited patch and plaque) mycosis fungoides: A long- term outcome analysis

Archives of Dermatology

Volumn 132, Issue 11, 1996, Pages 1309-1313

  Kim, Youn H ^a,b   Jensen, Reini A ^a   Watanabe, Garrett L ^a   Varghese, Anna ^a   Hoppe, Richard I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; PSORALEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL FEATURE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN BIOPSY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ACTUARIAL ANALYSIS; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 0029855505     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.132.11.1309     Document Type: Article

References (14)

1. Hoppe R, Wood G, Abel E. Mycosis fungoides and the Sézary syndrome: pathology, staging. and treatment. Curr Probl Cancer. 1990;14:295-371.
2. Kuzel T, Roenigk HJ, Rosen S. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy. J Clin Oncol. 1991;9:1298-1313.
3. Green S, Byar D, Lamberg S. Prognostic variables in mycosis fungoides. Cancer. 1981;47:2671-2677.
4. Lamberg S, Green S, Byar D, Block J, Vonderheid E. Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med. 1984;100:187-192.
5. Sausville E, Eddy J, Makuch R, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med. 1988;109:372-382.
6. Weinstock M, Horm J. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides. Cancer. 198;62:1658-1661.
7. Marti R, Estrach T, Reverter J, Mascaro J. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol. 1991;127:1511-1516.
8. Kim Y, Bishop K, Varghese A, Hoppe R. Prognostic indicators in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol. 1995;131:1003-1008.
9. Bunn PJ, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep. 1979;63:725-728.
10. Hoppe R, Abel E, Deneau D, et al. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol. 1987;5:1796-1803.
11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:475-480.
12. Gehan E. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203-233.
13. Cox D, Snell E. Analysis of Binary Data. New York. NY: Chapman & Hall: 1989.
14. US Dept of Health and Human Servces Public Health Service, Centers for Disease Control. National Center for Health Statistics. US Decennial Life Tables. 1979 Through 1981. Hyattsville, Md: US Dept of Health and Human Services; 1988;1:12-15. Publication PHS 88-1150-2.